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MABLE investigated the efficacy and safety of rituximab plus ben-damustine or rituximab plus chlorambucil in fludarabine-ineli-gible patients with chronic lymphocytic leukemia. Patients
received rituximab plus bendamustine or rituximab plus chlorambucil
every four weeks for six cycles. Rituximab plus chlorambucil-treated
patients without a complete response after Cycle 6 received chlorambu-
cil monotherapy for at least six additional cycles or until complete
response. The primary endpoint was complete response rate (confirmed
by bone marrow biopsy) after Cycle 6 in first-line patients. Secondary
endpoints included progression-free survival, overall survival, minimal
residual disease, and safety. Overall, 357 patients were randomized (rit-
uximab plus bendamustine, n=178; rituximab plus chlorambucil, n=179;
intent-to-treat population), including 241 first-line patients (n=121 and
n=120, respectively); 355 patients received treatment (n=177 and n=178,
respectively; safety population). In first-line patients, complete response
rate after Cycle 6 (rituximab plus bendamustine, 24%; rituximab plus
chlorambucil, 9%; P=0.002) and median progression-free survival (ritux-
imab plus bendamustine, 40 months; rituximab plus chlorambucil, 
30 months; P=0.003) were higher with rituximab plus bendamustine
than rituximab plus chlorambucil. Overall response rate and overall sur-
vival were not different. In first-line patients with a complete response,
minimal residual disease-negativity was higher with rituximab plus ben-
damustine than rituximab plus chlorambucil (66% vs. 36%). Overall
adverse event incidence was similar (rituximab plus bendamustine,
98%; rituximab plus chlorambucil, 97%). Rituximab plus bendamustine
may be a valuable first-line option for fludarabine-ineligible patients
with chronic lymphocytic leukemia. clinicaltrials.gov identifier: 01056510
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ABSTRACT
Introduction
Rituximab plus fludarabine and cyclophosphamide (R-FC) is standard treatment
for medically fit chronic lymphocytic leukemia (CLL) patients,1,2 with high response
rates in previously untreated patients (first-line; 1L) and treated patients (second-
line; 2L).3-5 However, many CLL patients are elderly and have comorbidities, mak-
ing them ineligible for fludarabine-based treatment.6 Chemotherapy options for
these patients include bendamustine (B) and chlorambucil (Clb).
In treatment-naïve CLL patients, phase II studies
showed promising efficacy with rituximab plus B (R-B)7 or
Clb (R-Clb),8,9 while the phase III CLL11 study demon-
strated improved efficacy with R-Clb and obinutuzumab
plus Clb (G-Clb) versus Clb monotherapy.10,11 G-Clb also
increased progression-free survival (PFS) and complete
response (CR) rates versus R-Clb,10,11 although infusion-
related reactions and neutropenia were more common;
infection rates were not increased, however.10 While a
phase III study demonstrated superior efficacy in terms of
CR and PFS with B versus Clb in treatment-naïve CLL,12,13
the activity of R-B versus R-Clb has not been directly com-
pared.
Herein, we present results from the randomized, open-
label, multicenter, phase IIIb MABLE study, which aimed
to investigate the efficacy and safety of R-B and R-Clb in
fludarabine-ineligible CLL patients.
Methods 
Study design 
Patients received rituximab (intravenous 375 mg/m2 Day [D] 1,
Cycle [C] 1 and 500 mg/m2 D1, C2-C6) plus B (intravenous 90
mg/m2 [1L] or 70 mg/m2 [2L] D1 and D2, C1-C6) or Clb (oral 10
mg/m2 D1-D7, C1-C6) every four weeks for six cycles. R-Clb
patients without CR after C6 received Clb monotherapy for ≤6
additional cycles or until CR. After treatment completion, patients
were followed every three months for one year, then every six
months until data cut-off. Treatment was discontinued if the
patient had progressive disease.
MABLE was conducted in accordance with the Declaration of
Helsinki, Good Clinical Practice guidelines, and local laws, and
approved by institutional review boards and ethics committees at
participating centers. All patients provided written informed con-
sent.
Patients
Patients were aged ≥18 years, with confirmed CLL requiring
treatment as per the International Workshop on CLL (iwCLL) cri-
teria,14 Binet stage B/C disease, Eastern Cooperative Oncology
Group (ECOG) performance status ≤2, and investigator assess-
ment of ineligibility for fludarabine-based treatment (Online
Supplementary Information). Exclusion criteria included transforma-
tion to aggressive B-cell malignancy and previous malignancy
within five years of enrollment (unless treated with curative
intent). For full inclusion and exclusion criteria see the Online
Supplementary Information.
During recruitment, the protocol was amended to permit inclu-
sion of patients with progressive Binet stage A disease and to
exclude 2L patients (due to slow recruitment). All 2L patients
recruited before this amendment were included in the final analy-
sis, as tumor response in this patient subpopulation was a second-
ary study endpoint; however, as the number of 2L patients
enrolled was relatively small, there was insufficient power to
show statistically significant differences between study treat-
ments in this patient subpopulation.
Study endpoints
The primary endpoint was CR rate (confirmed by bone marrow
[BM] biopsy) after C6 in 1L patients. Secondary endpoints includ-
ed CR rate after C6 in 2L patients, PFS, overall survival (OS), time
to next leukemic treatment, minimal residual disease (MRD), and
safety. Response was assessed after C3 and C6 as per iwCLL 2008
guidelines.14 Response was also assessed in the R-Clb arm at C12,
with treatment being discontinued for patients showing evidence
of CR during C7-C12. Assessments are detailed in the Online
Supplementary Information.
Safety
Adverse events (AEs) were monitored throughout the study and
graded according to the National Cancer Institute Common
Terminology Criteria for AEs v4.0 and coded according to the
Medical Dictionary for Regulatory Activities v17.0.
Statistical analysis
Efficacy analyses were conducted on the intent-to-treat (ITT)
population (all randomized patients). The safety population
included all randomized patients who received treatment.
For 1L patients, the between-arm difference in response rates
was tested using a one-sided continuity-corrected χ2 test. A two-
sided continuity-corrected χ2 test assessed between-arm differ-
ences in overall response rates (ORRs) and molecular responses.
PFS and OS were summarized by Kaplan–Meier estimates and
compared via the log-rank test. Hazard ratios (HRs) and 95% con-
fidence intervals (CIs) were calculated based on the Cox propor-
tional hazard model, with and without baseline Binet stage as a
covariate.
Results
Patients
The study was conducted between 23 February 2010
and 31 March 2014. Of the 357 patients in the ITT popu-
lation, comprising 241 1L patients (R-B, n=121; R-Clb,
n=120) and 116 2L patients (R-B, n=57; R-Clb, n=59), 355
received treatment (R-B, n=177; R-Clb, n=178). Ninety-
five patients (27%) withdrew from treatment during the
study (Figure 1).
Overall, 92/120 (76.7%) 1L patients treated with R-B
and 97/120 (80.8%) 1L patients treated with R-Clb
received six cycles of rituximab; 92 (76.7%) and 57
(47.5%) received six cycles of B and Clb, respectively.
Twelve (10.0%) patients treated with R-Clb received 12
cycles of Clb. The median number of R, B and Clb doses
was six for each. The median (interquartile range) dose of
rituximab was 4780.5 mg (4222.5-5346.5) in 1L patients
treated with R-B and 5028.5 mg (4546.0-5349.0) in 1L
patients treated with R-Clb. In total, 6/121 (5.0%) patients
treated with R-B and 2/120 (1.7%) patients treated with R-
Clb had a reduction or delay in their treatment schedule
due to treatment-emergent toxicities.
Baseline characteristics were balanced in the 1L popula-
tion (Table 1; baseline characteristics for all patients are
presented in Online Supplementary Table S1). Deletion of
17p was not an exclusion criterion due to a lack of efficacy
data relating to 17p deletion for the treatment combina-
tions used at the time of study design. Thus, 13 1L
patients (R-B, 10; R-Clb, 3) with 17p deletion were includ-
ed. Median follow-up was 23.5 months (R-B) and 23.3
months (R-Clb). Median age in 1L patients was 72 years in
both treatment arms; the majority of patients were aged
65 years or more. The median number of comorbidities
(active medical conditions) in 1L patients was three in
both arms (Table 1); the most common comorbidities
were vascular disorders and metabolism disorders affect-
ing 49% and 37% of patients, respectively (Online
Supplementary Table S2). The great majority of all patients
in the study (including 2L patients) used concomitant
medication during the study (R-B, 96%; R-Clb, 94%).
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Table 1. Demographic characteristics for patients receiving 1L therapy.
1L therapy
R-B R-Clb
(N=121) (N=120)
Age (years)
Median (min, max) 72 (41, 86) 72 (38, 91)
≥65 years, n (%) 86 (71) 90 (75)
≥75 years, n (%) 45 (37) 44 (37)
Sex
Male, n (%) 70 (58) 80 (67)
Female, n (%) 51 (42) 40 (33)
Active medical conditions, n
Median (min, max) 3 (0, 12) 3 (0, 18)
Binet stage, n (%)
A 6 (5) 8 (7)
B 73 (60) 66 (55)
C 37 (31) 43 (36)
Missing 5 (4) 3 (3)
ECOG PS, n (%)
0 62 (51) 59 (49)
1 50 (41) 51 (43)
2 9 (7) 8 (7)
Missing 0 2 (2)
Body surface area, m2
Mean (SD) 1.811 (0.2382) 1.807 (0.1706)
Min, max 1.30, 2.48 1.41, 2.29
IGVHmutational status, n (%)
Mutated 41 (34) 46 (38)
Unmutated 73 (60) 59 (49)
Othera 3 (3) 8 (7)
Not tested 4 (3) 7 (6)
11q status, n (%)
Heterozygous deletion 24 (20) 19 (16)
Normal 96 (79) 99 (83)
Not tested 1 (1) 2 (2)
17p status, n (%)
Heterozygous deletion 10 (8) 3 (3)
Normal 110 (91) 114 (95)
Not tested 1 (1) 3 (3)
11q/17p deletion, n (%)
Heterozygous deletion 32 (26) 22 (18)
Normal 88 (73) 96 (80)
Not tested 1 (1) 2 (2)
13q deletion (S25 or S319 probe)b, n (%)
Homozygous deletion 3 (3) 1 (1)
Two clones (one homozygote, one heterozygote) 15 (12) 6 (5)
Heterozygous deletion 42 (35) 5 (4)
Normal 61 (50) 60 (50)
Not tested 1 (1) 2 (2)
Trisomy 12, n (%)
Trisomy 30 (25) 19 (16)
Normal  90 (74) 99 (83)
Not tested 1 (1) 2 (2)
aOther includes polyclonal and oligoclonal. bDeletion status according to at least one probe (NB, in the R-B group, one patient with two clones by S319 probe and heterozygous
deletion by S25 probe is counted twice). 1L: first-line; ECOG PS: Eastern Cooperative Oncology Group performance status; R-B: rituximab plus bendamustine; R-Clb: rituximab
plus chlorambucil; SD: standard deviation. 
Colony-stimulating factors were taken more frequently
by patients treated with R-B (111/178 [62.4%] vs. 71/179
[39.7%] for R-Clb). ECOG performance status scores were
≥1 in approximately half the study population. At base-
line, 108/177 (61.0%), 56/177 (31.6%) and 4/177 (2.3%)
patients treated with R-B, and 102/178 (57.3%), 60/178
(33.7%) and 3/178 (1.7%) patients treated with R-Clb had
normal; abnormal, non-clinically significant; and abnor-
mal clinically significant calculated creatinine clearance,
respectively.
Efficacy
In 1L patients, the CR rate after C6 was higher with R-
B versus R-Clb (24% [n=29/121] vs. 9% [n=11/120];
P=0.002; Table 2). Logistic regression analysis supported
the R-B treatment effect after adjusting for baseline covari-
ates (odds ratio 4.18, 95% CI 1.77-9.87; P=0.001). None of
the covariates had a statistically significant impact on the
CR rate. 
ORRs (based on the investigator’s assessment) at the
end of rituximab treatment were similar for R-B and R-Clb
(91% vs. 86%; P=0.304). The proportion of patients with
stable disease (3% vs. 6%) and progressive disease (3% vs.
2%) at the end of treatment were also similar for R-B vs.
R-Clb, respectively.
A statistically significant ten-month extension in medi-
an PFS was observed with R-B versus R-Clb (39.6 vs. 29.9
months; HR [adjusted for baseline Binet stage] 0.523, 95%
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Figure 1. Patient disposition. Numbers in parentheses represent the number of patients from the 1L subpopulation. In total, 118 patients (33%) discontinued the
study prematurely, due to death (R-B 16%; R-Clb 19%), patient lost to follow-up (3% per arm), investigator decision (R-B 2%; R-Clb 3%), patient withdrew consent 
(R-B 3%; R-Clb 2%), patient non-compliance (R-B 1%; R-Clb 2%), and ‘other’ reasons (R-B 6%; R-Clb 7%). Reason for withdrawal was not available for one patient 
(R-Clb). AE: adverse event; C: cycle; N: number of patients; PD: progressive disease; R-B: rituximab plus bendamustine; R-Clb: rituximab plus chlorambucil.
Table 2. CR and PRs at C6 in 1L patients.
Assessment Analysis R-B R-Clb
CR confirmed by BM biopsya CR N 121 120
n (%) 29 (24) 11 (9)
P-valueb 0.002
Logistic regressionc N 113 103
OR (95% CI) 4.18 (1.77-9.87)
P-valued 0.001
PR based on the investigator’s assessment PR N 121 120
n (%) 60 (50) 79 (66)
aCRs confirmed by BM biopsy only were included. bP-value is based on a one-sided continuity corrected χ2 test. cThe following covariates were included in the logistic regression:
Binet stage (A and B vs. C); IGVHmutational status (mutated vs. unmutated); 17p/11q deletion (heterozygote deletion vs. normal); ECOG PS (0 vs. ≥1). dP-value is based on the
Wald test. BM: bone marrow; CI: confidence interval; CR: complete response; OR: odds ratio; PR: partial response; R-B: rituximab plus bendamustine; R-Clb: rituximab plus chlo-
rambucil.
CI 0.339-0.806; P=0.003; Figure 2A); median OS was not
significantly different (43.8 months vs. not reached; HR
[adjusted for baseline Binet stage] 0.975, 95% CI 0.505-
1.880; P=0.939; Figure 2B). During the study, 11/121
(9.1%) patients treated with R-B and 22/120 (18.3%)
patients treated with R-Clb had a documented intake of
any new leukemia treatment. Due to the low numbers,
the median time to next leukemic treatment could not be
calculated for either treatment arm (log-rank test for com-
parison between treatment arms: P=0.037).
MRD data were available for 45/50 patients (90%) who
had a CR based on the investigator’s assessment and
182/241 patients (76%) overall. BM aspirates were avail-
able for 42/45 patients (93%) and 145/182 patients (80%),
respectively. MRD-negativity rates at the confirmation-of-
response visit (ITT population) were higher for R-B than
for R-Clb (41% vs. 13%; Table 3). In 1L patients with a CR
after C6, MRD-negativity rates at the confirmation-of-
response visit were higher in the R-B group than in the R-
Clb group (66% vs. 36%). A similar pattern was seen in
those with a CR or PR according to investigator’s assess-
ment (53% vs. 18%).
Efficacy results in 2L patients are presented in the Online
Supplementary Information.
Safety
Safety results are presented for the pooled population
(1L and 2L patients). AEs were similar between arms (R-B,
98%; R-Clb, 97%; Table 4). The most common AEs by
System Organ Class (SOC) were ‘blood and lymphatic
system disorders’ (R-B, 75%; R-Clb, 64%); the most com-
monly reported AE was neutropenia (R-B, 56%; R-Clb,
49%). AEs in the SOC ‘skin and subcutaneous tissue dis-
orders’ were more frequent in the R-B versus R-Clb arm
(36% vs. 23%), driven by a higher incidence of rash (16%
vs. 5%).
Grade ≥3 AEs were higher with R-B (75%) than R-Clb
(64%), mainly due to a higher incidence of serious AEs
(SAEs) of the SOC ‘infections and infestations’. The most
common grade ≥3 AEs were of the SOC ‘blood and lym-
phatic system disorders’ (R-B, 56%; R-Clb, 47%). SAEs
were experienced by 41% (R-B) and 32% (R-Clb) of
patients, and were most frequently of the SOC ‘infections
and infestations’ (R-B, 19%; R-Clb, 8%; Table 4).
Rituximab-related AEs were experienced by 81% (R-B)
and 73% (R-Clb) of patients. B/Clb-related AEs were
reported for 92% (R-B) and 80% (R-Clb) of patients. Drug-
related AEs (rituximab, B, and Clb) were most commonly
of the SOC ‘blood and lymphatic system disorders’. AEs
leading to rituximab discontinuation were experienced by
18% (R-B) and 11% (R-Clb) of patients. AEs leading to dis-
continuation of B or Clb were reported for 19% and 18%
of patients, respectively. In 1L patients, AEs leading to
treatment discontinuation were experienced by 22 R-B
patients (18%) and 14 R-Clb patients (12%).
Overall, 65 patients died (R-B, n=30, 17%; R-Clb, n=35,
20%) due to CLL (R-B, n=14, 8%; R-Clb, n=20, 11%) and
AEs (R-B, n=16, 9%; R-Clb, n=14, 8%). Cause of death
was missing for one patient (R-Clb arm). AEs leading to
death were infection (n=4 per arm), acute myeloid
leukemia or myelodysplastic syndrome (n=1 per arm),
other neoplasm (R-Clb, n=1), and other causes (R-B, n=11;
R-Clb, n=8). Treatment-related AEs leading to death
included thrombocytopenia, neutropenic sepsis and
febrile neutropenia (n=1 each) in the 1L population and
multi-organ failure, pneumonia, acute myeloid leukemia
and sepsis (n=1 each) in the 2L population. 
Discussion
R-FC is the standard 1L treatment for medically-fit
patients with CLL. However, this regimen can cause sig-
nificant myelosuppression and high rates of early and late
infections, especially in elderly patients15 who may have
comorbidities and be considered ineligible for fludarabine-
based treatment.6 In MABLE, the efficacy and safety of R-
B and R-Clb were investigated in fludarabine-ineligible
CLL patients. B is an established treatment for CLL, and a
previous phase III study of B versus Clb in treatment-naïve
patients demonstrated improved CR rates and median PFS
with B.12,13 R combined with chemotherapeutic agents pro-
longs OS in previously untreated, medically fit CLL
patients.16,17 In unfit patients, survival was improved by the
addition of G to Clb.10
Among 1L patients in MABLE, the rates of CR and of
CR with MRD-negativity were higher for R-B than for R-
Clb. ORRs were similar in the two arms. Whereas the CR
rate in 1L R-Clb patients in MABLE (9%) was comparable
with that in R-Clb patients in the phase III CLL11 study
(7%),10 the ORR for R-Clb-treated patients was higher in
MABLE than in CLL11 (86% vs. 58%). Two explanations
for this might be the different Clb doses used (MABLE, 10
A.-S. Michallet et al.
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Table 3. MRD negativity at the confirmation-of-response visita in 1L patients.
                                                                                                        R-B                                                       R-Clb
Overall ITT population                                                                                 (n=121)                                                            (n=120)
MRD-negative patients, n (%)                                                                  49 (41)                                                               16 (13)
Patients with CR                                                                                             (n=29)                                                              (n=11)
MRD-negative patients, n (%)                                                                  19 (66)                                                                4 (36)
Patients with CR or PR based on the 
investigator’s assessmentb                                                                          (n=89)                                                              (n=90)
MRD-negative patients, n (%)                                                                  47 (53)                                                               16 (18)
aPerformed 12 weeks after the end of C6 disease response assessment. bIncludes patients with CR (with or without BM confirmation) or PR by investigator assessment. Negative
MRD was defined as proportion of malignant B cells to white blood cells of <10-4, as assessed by allele-specific oligonucleotide real-time quantitative polymerase chain reaction
assay measured in BM aspirate (or PB if BM unavailable). MRD data were available for 45/50 patients with a CR based on the investigator’s assessment (BM, n=42; PB, n=1;
unknown=2) and 182/241 patients overall (BM, n=145; PB, n=32; unknown=5).  CR: complete response; ITT: intent-to-treat; MRD: minimal residual disease; PR: partial response; RB:
rituximab plus bendamustine; R-Clb: rituximab plus chlorambucil.
mg/m2; CLL11, 0.5 mg/kg), which resulted in a higher
median cumulative dose (MABLE, 720 mg; CLL11, 366-
400 mg), and differences in the study populations, with
patients in MABLE having fewer active comorbidities
than those in CLL11 (medians of 3 and 5, respectively) and
a better performance status.10 Earlier phase II studies in
elderly CLL patients treated 1L with R-Clb reported CR
rates of 10-17% and ORRs of 82-84%.8,9 The CLL2M trial,
a phase II study of CLL patients treated 1L with R-B, at the
same B dosage as the current study, reported a CR rate of
23% and an ORR of 88%.7
In 1L patients in the study reported herein, the median
PFS of 39.6 months in the R-B arm was significantly longer
(by 10 months) than the value in the R-Clb arm. This
result is similar to the median PFS of 43.2 months
achieved in fit CLL patients treated with R-B in the CLL10
study,18 and is consistent with the findings of the CLL2M
study, which enrolled fit and unfit 1L patients and report-
ed a median event-free survival in R-B-treated patients of
33.9 months.7 The CLL2M study did not select patients by
fitness, but a substantial proportion could be considered
unfit based on age, Binet stage, and renal impairment.7 In
MABLE, 33% of the 1L patients were Binet stage C and
the median age was 72 years. The PFS result in the R-Clb
arm in MABLE was almost twice as long as that in CLL11
(29.9 vs. 15.4 months),11 however, as noted above, a direct
comparison of these studies is limited by differences in
Clb doses and patient fitness.
In MABLE, 1L patients with CR had higher MRD-nega-
tivity rates with R-B versus R-Clb, indicating a greater
depth of response with R-B. Of note, MRD was assessed
primarily in BM from patients with CR based on the
investigator’s assessment, whereas in CLL11 and previous
phase II studies, MRD was measured in peripheral blood
([PB] or BM) from all patients.7,8,10 One phase II study
reported a MRD-negativity rate of 12.5% (2/16 patients)
using BM aspirates from R-Clb-treated patients who
achieved a CR/unconfirmed CR.9
Median OS was not significantly different between
treatment arms in 1L patients in MABLE and was not
reached in previous phase II studies of R-B and R-Clb,7-9 or
in the CLL11 and COMPLEMENT-1 studies.11,19 At current
follow-up reported for CLL11 and COMPLEMENT-1, no
significant OS benefit was observed for G-Clb versus
R-Clb or ofatumumab plus Clb (Ofa-Clb) versus Clb,
respectively,11,19 whereas a significant improvement was
observed for G-Clb versus Clb alone.10 Further observation
is required to determine if there is an OS benefit with 
G-Clb versus R-Clb or Ofa-Clb versus Clb.
Safety profiles (for pooled 1L and 2L patients) were sim-
ilar for R-Clb and R-B, with no new or clinically relevant
safety signals, and events were as expected for CLL
patients receiving immunochemotherapy.7-9 Incidences of
all-grade AEs, SAEs, and treatment-related AEs were sim-
ilar across arms. Grade ≥3 AE incidence was slightly high-
er with R-B versus R-Clb, driven by a higher incidence of
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Figure 2. Efficacy in 1L patients. (A) PFS and (B) OS. CI: confidence interval; HR: hazard ratio; NR: not reached; OS: overall survival; PFS: progression-free survival;
R-B: rituximab plus bendamustine; R-Clb: rituximab plus chlorambucil.
A
B
infections and infestations. Few patients in either arm dis-
continued therapy due to AEs. Treatment withdrawal due
to AEs was reported for 18% of patients receiving 1L R-B
and 12% receiving R-Clb.
As previously noted, the results of the CLL11 study
show that, in unfit CLL patients, G-Clb was associated
with higher response rates and longer PFS than R-Clb,
with more frequent MRD eradication and an acceptable
toxicity profile.10 In addition, current guidelines,
(European Society for Medical Oncology and National
Comprehensive Cancer Network), recommend Clb in
combination with an anti-CD20 antibody as standard 1L
therapy in unfit CLL patients.20,21 However, in MABLE and
previous studies, R-B was associated with a good response
rate and improved PFS compared with R-Clb. Currently,
evidence to guide the choice between R-B and G-Clb in 1L
unfit patients with CLL is limited, although a recent meta-
analysis of PFS and OS results in five studies showed a
trend towards better efficacy for G-Clb than R-B;22 how-
ever, the difference was not significant despite a signifi-
cant difference between G-Clb and other comparators
such as R-Clb, Ofa-Clb, Clb, and fludarabine. A random-
ized trial comparing these combinations could resolve this
question.
Some limitations of our study should be acknowledged.
Since we relied only on investigator assessments of tumor
response to evaluate efficacy, and did not include assess-
ments by an independent review committee, this might
have introduced a potential bias in the efficacy results.
Comparison of our results with those of other studies in
CLL patients is potentially complicated because the selec-
tion of patients based on fitness was based on a judgment
made by the investigator that the patients were not eligi-
ble for fludarabine, according to a set of pre-defined crite-
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Table 4. Summary of AEs (safety population).
Patients, n (%) R-B R-Clb
(N=177) (N=178)
All-grade AEs 173 (98) 173 (97)
Grade ≥3 AEs 132 (75) 113 (64)
SAEs 73 (41) 56 (32)
Most common all-grade AEsa
Blood and lymphatic system disorders 133 (75) 113 (64)
Neutropenia 99 (56) 88 (49)
Leukopenia 42 (24) 31 (17)
Anemia 41 (23) 27 (15)
Thrombocytopenia 37 (21) 44 (25)
Lymphopenia 30 (17) 21 (12)
Gastrointestinal disorders 99 (56) 90 (51)
Nausea 53 (30) 46 (26)
Diarrhea 30 (17) 22 (12)
Constipation 28 (16) 23 (13)
General disorders and administrative site conditions 93 (53) 87 (49)
Pyrexia 37 (21) 17 (10)
Asthenia 29 (16) 34 (19)
Skin and subcutaneous tissue disorders 63 (36) 40 (23)
Rash 29 (16) 9 (5)
Most common grade ≥3 AEsb
Blood and lymphatic system disorders 99 (56) 84 (47)
Neutropenia 76 (43) 65 (37)
Leukopenia 29 (16) 15 (8)
Anemia 18 (10) 12 (7)
Lymphopenia 17 (10) 10 (6)
Thrombocytopenia 17 (10) 16 (9)
Febrile neutropenia 12 (7) 7 (4)
Most common SAEsb
Infections and infestations 33 (19) 15 (8)
Pneumonia 8 (5) 2 (1)
Blood and lymphatic system disorders 25 (14) 15 (8)
Febrile neutropenia 11 (6) 7 (4)
aPreferred terms with incidence of ≥15% in either study arm. bPreferred terms with incidence of ≥5% in either study arm.  Non-serious AEs were reported until 28 days after the
end of the last treatment cycle. SAEs unrelated to study treatment were reported until six months after the end of treatment or until the start of new anti- chronic lymphocytic
leukemia treatment. Treatment-related SAEs were to be reported indefinitely.  AE: adverse event; R-B: rituximab plus bendamustine; R-Clb: rituximab plus chlorambucil; SAE: seri-
ous adverse event. 
ria that were based on the prescribing information for flu-
darabine at the time of study design; the Cumulative
Illness Rating Scale scoring was not used. However, a
recent randomized study comparing the efficacy of ibruti-
nib with Clb used an age cut-off of 65 years as the only
criterion for selecting “older” patients, and did not carry
out any assessment of comorbidities.23
Although the efficacy of immunochemotherapy combi-
nations such as R-B, Ofa-Clb, and G-Clb in CLL have been
shown,7,11,19 obinutuzumab plus B (G-B) needs to be evalu-
ated further, although it is likely that future clinical studies
will focus more on the combination of anti-CD20 anti-
bodies with novel agents such as ibrutinib, idelalisib, and
venetoclax. Indeed, these agents have shown promising
efficacy when combined with anti-CD20 monoclonal
antibodies (including rituximab) in the relapsed/refractory
CLL setting,24-29 and are now being evaluated in 1L.23
Furthermore, additional safety data for 1L B-cell receptor
(BCR) signaling inhibitors are required. In March 2016, the
US Food and Drug Administration alerted healthcare pro-
fessionals about safety concerns with idelalisib when used
in combination with rituximab or R-B in CLL and follicu-
lar lymphoma. This was related to a high rate of viral and
fungal infections that led the sponsor to discontinue six
trials.30
However, given the economic burden associated with
new agents and the fact that  BCR inhibitors are not yet
available in many European countries, immunochemother-
apy combinations are likely to continue to be valuable treat-
ment options for 1L patients with CLL.31
In conclusion, in fludarabine-ineligible CLL patients, 1L
R-B treatment significantly improved CR rates and medi-
an PFS versus R-Clb, and increased MRD-negativity rates,
with no new safety signals reported. R-B may be a valu-
able 1L option for fludarabine-ineligible CLL patients and
this combination continues to be widely used in clinical
practice in Europe, reinforcing the interest of this large
randomized study.
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